BioMarin Pharmaceutical vs Repligen

BioMarin Pharmaceutical (BMRN), health care, and Repligen (RGEN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

BioMarin Pharmaceutical is worth $11.3B on the stock market and Repligen $10.4B: BioMarin Pharmaceutical is valued at 9% more. BioMarin Pharmaceutical's operating margin in its latest fiscal year was 12.7% and Repligen's 7.47%. Over the past year BioMarin Pharmaceutical's share price has moved +7.07% and Repligen's +6.35%.

Key facts

BioMarin Pharmaceutical market value
$11.3B
Repligen market value
$10.4B
BioMarin Pharmaceutical revenue
$3.2BFY to 2025-12-31
Repligen revenue
$738.3MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

BioMarin Pharmaceutical vs Repligen: every measure side by side
Measure BioMarin Pharmaceutical Repligen
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$11.3Bhigher$10.4Blower
Revenue$3.2Bhigher$738.3Mlower
Earnings$348.9Mhigher$48.9Mlower
Employees3,221higher2,000lower
Total assets$7.6Bhigher$2.9Blower
Valuation
P/E——
P/S3.5lower14.0higher
P/B1.8lower4.4higher
Dividend yield0.00%0.00%
Profitability
Operating margin12.7%higher7.47%lower
Balance sheet
Net assets$6.1Bhigher$2.1Blower
Total liabilities$1.5Bhigher$843.6Mlower
Total debt—$542.2M
Cash on hand$1.3Bhigher$566Mlower
Price change
Today+0.90%higher-0.37%lower
1 year+7.07%higher+6.35%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

BioMarin Pharmaceutical only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns BMRN · Who owns RGEN

Further comparisons

Learn

Questions and answers

Which is bigger, BioMarin Pharmaceutical or Repligen?

By market value, BioMarin Pharmaceutical is the larger: $11.3B against $10.4B for Repligen. By revenue in its latest fiscal year, BioMarin Pharmaceutical is the larger: $3.2B against $738.3M for Repligen.

Which has the higher operating margin?

BioMarin Pharmaceutical: 12.7%, against 7.47% for Repligen. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both BioMarin Pharmaceutical and Repligen?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold BioMarin Pharmaceutical and 6 hold Repligen.

Cite this page

Funkfolio, “BioMarin Pharmaceutical vs Repligen”, data as of 18 November 2026. https://funkfolio.com/compare/bmrn-vs-rgen

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.